Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter April 1, 2020

Decision-making based on sFlt-1/PlGF ratios: are immunoassay results interchangeable for diagnosis or prognosis of preeclampsia?

  • Guillaume Lefèvre EMAIL logo , Alexandre Hertig , Jean Guibourdenche , Pacifique Lévy , Sophie Bailleul , Dominique Drouin , Florence Batusanski , Fabien Guimiot and Henri Boulanger


The authors wish to thank Dr. Safouane Hamdi (Biochimie et Hormonologie, CHU de Toulouse, France) for the fruitful discussions.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


1. Stepan H, Hund M, Dilba P, Sillman J, Schlembach D. Elecsys® and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable? Clin Chem Lab Med 2019;57:1339–48.10.1515/cclm-2018-1228Search in Google Scholar PubMed

2. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2014; 63:346–52.10.1161/HYPERTENSIONAHA.113.01787Search in Google Scholar PubMed

3. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012;206:58.e1–8.10.1016/j.ajog.2011.07.037Search in Google Scholar PubMed

4. Chan SL, Rana S, Chinthala S, Salahuddin S, Yeo KJ. Analytical validation of soluble fms-like tyrosine and placental growth factor assays on B·R·A·H·M·S KRYPTOR Compact Plus automated immunoassay platform. Pregnancy Hypertens 2018;11:66–70.10.1016/j.preghy.2017.12.009Search in Google Scholar PubMed

5. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010;202:161.e1–11.10.1016/j.ajog.2009.09.016Search in Google Scholar PubMed

6. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, et al. Predictive value of the sFlt-1: PlGF ratio in women with suspected preeclampsia. N Engl J Med 2016;374:13–22.10.1097/01.ogx.0000482523.79556.f6Search in Google Scholar

7. National Institute for Health and Care Excellence. PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio). Diagnostics guidance Published: 11 May 2016 in Google Scholar

8. Stepan H, Herraiz I, Schlembach D, Verlohren S, Brennecke S, Chantraine F, et al. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol 2015;45:241–6.10.1002/uog.14799Search in Google Scholar PubMed PubMed Central

9. Gómez-Arriaga PI, Herraiz I, López-Jiménez EA, Escribano D, Denk B, Galindo A. Uterine artery Doppler and sFlt-1/PlGF ratio: prognostic value in early-onset pre-eclampsia. Ultrasound Obstet Gynecol 2014;43:525–32.10.1002/uog.13224Search in Google Scholar PubMed

10. Van Helden J, Weiskirchen R. Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia. Clin Biochem 2015;48:1113–9.10.1016/j.clinbiochem.2015.06.020Search in Google Scholar PubMed

11. Andersen LB, Frederiksen-Møller B, Work Havelund K, Dechend R, Jørgensen JS, Jensen BL, et al. Diagnosis of preeclampsia with soluble fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison. J Am Soc Hypertens 2015;9:86–96.10.1016/j.jash.2014.11.008Search in Google Scholar PubMed

12. Salahuddin S, Wenger JB, Zhang D, Thadhani R, Karumanchi SA, Rana S. KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes. Hypertens Pregnancy 2016;35:330–45.10.3109/10641955.2016.1148162Search in Google Scholar PubMed

13. Cheng YK, Poon LC, Shennan A, Leung TY, Sahota DS. Inter-manufacturer comparison of automated immunoassays for the measurement of soluble fms-like tyrosine kinase-1 and placental growth factor. Pregnancy Hypertens 2019;17:165–71.10.1016/j.preghy.2019.06.004Search in Google Scholar PubMed

Received: 2020-01-22
Accepted: 2020-02-24
Published Online: 2020-04-01
Published in Print: 2021-02-23

©2020 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 2.12.2023 from
Scroll to top button